ideasIdea
Social impact bonds that fund biosimilar switching, repaid from payer savings
Hospitals often lack the staff to switch patients to cheaper equivalent drugs. Private investors could fund the switching teams and be repaid by the health system from the money saved.
Switching programmes (pharmacists, patient information, prescribing system changes) have a very high return but compete for scarce operating budgets. A social impact bond raises private capital to fund the programme and repays investors, with a return, from verified savings measured against a pre-agreed baseline; the payer pays only if savings materialise. Social impact bonds have been used in social care and public health; oncology drug switching has an unusually measurable outcome.
Hypothesis
Bond-funded switching programmes achieve biosimilar and generic shares above 85% within a year and generate verified savings at least five times the programme cost, with investors repaid in full.
Rationale
The savings from switching are large, fast and measurable from claims data, which is exactly the profile that makes outcome-based financing work; the constraint is up-front capacity, which the bond supplies.
What would test it
Structure one bond covering ten hospitals for two new oncology biosimilar launches, with an independent evaluator verifying savings, and publish the returns and clinical safety data.
Maturity
speculative
Who has to act
philanthropy
Cost to try
Medium ($1M to $50M)
Years to first evidence
2
Bottlenecks it attacks
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.